Ondansetron Dydrochloride Dihydrate Aurobindo (Ondansetron)

Ondansetron is a selective serotonin 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways.

• Chemotherapy‑induced nausea and vomiting (CINV): reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting (RINV): helps control nausea during and after radiotherapy.
• Post‑operative nausea and vomiting (PONV): decreases the incidence of nausea and vomiting after surgical procedures.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signaling cascade that initiates the vomiting reflex, thereby providing anti‑emetic protection.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel movement difficulty.
• Diarrhoea: loose stools in a minority of patients.
• Fatigue: general tiredness or lack of energy.
• Dizziness: sensation of light‑headedness.
• Injection site pain (if administered parenterally): localized discomfort.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm.
• Severe allergic reaction: rash, itching, swelling, or breathing difficulty.
• Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.
• Blood dyscrasias: uncommon reductions in white blood cells or platelets.
• Neuroleptic malignant‑like syndrome: extremely rare neurological emergency.

Before prescribing Ondansetron, consider the following precautions:

• Cardiac assessment: evaluate baseline ECG in patients with known heart disease or electrolyte abnormalities.
• Electrolyte monitoring: correct potassium, magnesium, or calcium imbalances that could predispose to QT prolongation.
• Drug interactions: review concomitant medications that affect cardiac conduction or serotonin levels.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Renal/hepatic impairment: dose adjustment may be required in severe dysfunction.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Amiodarone: combined use can markedly increase QT‑interval prolongation risk.
• Certain anti‑arrhythmics (e.g., sotalol, quinidine): additive effects on cardiac repolarisation.
• Serotonergic agents (e.g., tramadol, linezolide) when used in high doses: heightened serotonin‑syndrome risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels.
• CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of their metabolism.
• Anticholinergic drugs: may blunt the anti‑emetic effect.
• Diuretics: electrolyte shifts can influence QT interval.
• Oral contraceptives: rare reports of reduced efficacy.